Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1538 7445 "

Sökning: L773:1538 7445

Sortera/gruppera träfflistan
  • C., Ellberg, et al. (författare)
  • Body constitution in young healthy women from breast cancer higher risk families in relation to smoking
  • 2017
  • Ingår i: Cancer Research. - : American Association for Cancer Research Inc.. - 1538-7445. ; 77:13
  • Konferensbidrag (refereegranskat)abstract
    • Introduction: The purpose of this study was to investigate potential associations between body composition and current smoking in young healthy women from high-risk families. Cigarette smoke contains >7000 chemicals of which 69 are established carcinogens and smoke also acts as an aromatase inhibitor. Smoking is now recognized as a carcinogen for the breast and influences both risk and prognosis. However, the underlying mechanisms need to be better elucidated. One study showed that breast cancer patients who smoked were younger, had a lower body mass index (BMI), smaller breast volumes, but a higher waist-to-hip ratio (WHR) than non-smokers. However, smoking was also associated with a higher frequency of prior oral contraceptive (OC) use. Since breast cancer development starts long before the tumor is clinically detectable, we aimed to study the impact of cigarette smoke on anthropometric factors. Material and methods: Between 1996 and 2006, 269 healthy women were included in a study on the impact of lifestyle factors in women 0.18). However, current smokers had significantly larger standardized waist circumference (78 vs 74 cm;adjP=0.02), and higher standardized WHR (0.79 vs 0.76;adjP=0.003) compared with non-smokers. Conclusion: Current smokers had significantly larger waist circumference and higher WHR, but similar BMI and breast volume compared with non-smokers, although most women had anthropometric measures within WHO's recommended limits. The difference in fat distribution towards more abdominal fat, suggests that current smoking is associated with a more inflammatory and/or androgenic profile at the age when breast cancer is initiated.
  • C., Ellberg, et al. (författare)
  • Smoking impacts endogenous estradiol and testosterone levels in young healthy women
  • 2017
  • Ingår i: Cancer Research. - : American Association for Cancer Research Inc.. - 1538-7445. ; 77:13 Suppl
  • Konferensbidrag (refereegranskat)abstract
    • Introduction: The purpose of the study was to elucidate the association between smoking and estradiol (E2) and testosterone (T) levels in young healthy women from highrisk families. Cigarette smoke contains multiple carcinogens and is considered a risk factor for breast cancer. However, tobacco also contains aromatase inhibiting substances, but the impact on hormonal levels in young women at the age when breast cancer is initiated is unclear and needs further elucidation. Material and methods Between 1996 and 2002, 258 healthy women from high-risk breast cancer families in Sweden were enrolled in a study on the impact of lifestyle factors in women
  • H.L., Olsson (författare)
  • With increasing age at tumor diagnosis in families with cancer, cancer is limited to fewer organs
  • 2016
  • Ingår i: Cancer Research. - : American Association for Cancer Research Inc.. - 1538-7445. ; 76:14 Suppl
  • Konferensbidrag (refereegranskat)abstract
    • Hereditary cancer that has monogenic inheritance affects every tenth patient, on average, who is diagnosed with cancer, and it has been suggested based on twin studies, that approximately 30% of all cancer patients have a genetic predisposition to developing cancer. The author posited that familial syndromes become more organ specific with increasing age at tumour presentation to the point that very late in life, only a few organs are affected by tumours disease. The reason for this could be that the tumour originates from a more differentiated, organ-specific progenitor/stem cell later in life, while the progenitor/stem cell might be involved in organogenesis in different organs earlier in life. Examples are given for skin cancer and breast cancer. Summary: Patients with familial cancer who present with cancer at an older age at tumour presentation have a more organ restricted disease. This could be because the tumor has a more differentiated progenitor/stem cell origin. Examples are given for families with breast cancer, melanoma, and non-melanoma skin cancer.
  • Schrijver, L, et al. (författare)
  • Oral contraceptive use and breast cancer risk: A cohort study of BRCA1 and BRCA2 mutation carriers
  • 2017
  • Ingår i: Cancer Research. - : American Association for Cancer Research Inc.. - 1538-7445. ; 77:13 Suppl 1
  • Konferensbidrag (refereegranskat)abstract
    • Background: BRCA1 and BRCA2 mutation carriers are at high risk of breast and ovarian cancer. Oral contraceptive preparations (OCPs) may reduce ovarian cancer risk, but its effect on breast cancer risk remains unclear. Methods: Combined data from three cohorts of 5705 BRCA1 and 3521 BRCA2 mutation carriers (IBCCS, BCFR and kConFab) were analyzed using age-dependent Cox regression models stratified for study and birth cohort. We conducted the first prospective analyses on this topic. Our additional main retrospective analyses were leftcensored 5 years preceding date of baseline questionnaire to control for survival bias. The full-cohort retrospective analyses, without left-censoring, was performed to compare results with the literature. Prospective analyses were considered most valid, while retrospective analyses were most powerful. Results: For BRCA1 mutation carriers we found no association between ever OCP use and risk of breast cancer in the prospective analyses (HR=1.08, 95% CI 0.75-1.56), but 23% and 27% increased risks for ever OCP use in the left-censored and full retrospective analyses, respectively. Retrospectively, an increasing trend for longer duration of use, especially before first full-term pregnancy (FFTP) was found (left-censored analyses: 10 years HR 1.41 (95%CI 1.10-1.813), p-trend=0.001 for duration of use before FFTP). For BRCA2 mutation carriers we found a positive association between ever OCP use and risk of breast cancer prospectively (HR=1.75, 95% CI 1.03-2.97), but retrospectively findings were inconsistent (HR=1.06, 95% CI 0.85-1.33 and HR=1.52, 95% CI 1.28-1.81 for the left-censored and full analyses, respectively). Conclusion: For BRCA1 mutation carriers the discrepancy between results of prospective and retrospective analyses may be explained by time since last OCP use before FFTP. Thus, a temporal increased risk of breast cancer following longer duration of OCP use before FFTP cannot be ruled out. The discordant findings between prospective and retrospective analyses for BRCA2 carriers could not be explained. Because of the lack of scientific clarity it is too early to give an unequivocal advice on OCP use with respect to breast cancer risk to BRCA1 and BRCA2 mutation carriers.
  • Ullmark, Tove, et al. (författare)
  • Global binding pattern of the Wilms' tumor gene 1 (WT1) +17AA -KTS isoform in leukemic cells
  • 2016
  • Ingår i: Cancer Research. - : American Association for Cancer Research Inc.. - 1538-7445. ; 76:14 Suppl.
  • Konferensbidrag (refereegranskat)abstract
    • The aim of this study was to investigate the global DNA-binding pattern of Wilms' tumor gene 1 (WT1) in leukemic cells. Clinical and preclinical data indicate the zinc finger transcription factor WT1 as an oncogene, but the full target gene repertoire of WT1 in leukemic cells has not been previously characterized. The -KTS isoforms (excluding the three amino acid (KTS) insert between zinc finger three and four) are considered as the most efficient DNA-binders. Among these, the 17AA isoform (including 17 amino acids encoded by exon 5) is the most abundant one. To specifically analyze the DNA-binding of WT1(+17AA/-KTS) in leukemic cells, we generated a K562 clone that stably expressed BIO-tagged WT1(+17AA/-KTS), as well as the biotinylating enzyme Bir A. From the cells chromatin immunoprecipitation (ChIP) by streptavidin capture was performed followed by sequencing with a minimum of 50 million reads per sample. After alignment to the genome and peak calling, peaks were characterized and compared to available K562 tracks in the ENCODE database. We found that 45% of identified WT1(+17AA/-KTS) peaks are in the proximity of transcription start sites (promoter area, first exon or first intron) of target genes, whereas only 11% of randomized peaks were found here. Within the peaks we show strong enrichment for three different previously published WT1-binding motifs. Comparison to ENCODE tracks showed that WT1(+17AA/-KTS) peaks are in close proximity to binding sites of other transcription factors, to histone marks for actively transcribed genes, and to binding sites of chromatin modifiers. Considering peaks within promoters and gene bodies only (for safe assignment to a target gene), Gene Ontology (GO) analysis revealed enrichment of GO groups important for proliferation, cell death, embryonic development, and cell motility. In conclusion, WT1(+17AA/-KTS) binds close to transcription start sites in areas of active transcription. The target genes implicated in proliferation, cell death, cell signaling and motility adds to the growing evidence of WT1 as an effector gene in leukemia.
  • Brueffer, Christian, et al. (författare)
  • Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study
  • 2018
  • Ingår i: Cancer research. Supplement. - : American Association for Cancer Research Inc.. - 1538-7445. ; 78:4
  • Konferensbidrag (refereegranskat)abstract
    • Background:In early breast cancer, five histopathological biomarkers are part of current clinical routines and used for determining prognosis and treatment: estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (ERBB2/HER2), Ki67, and Nottingham histological grade (NHG). We aimed to develop classifiers for these biomarkers based on tumor mRNA-sequencing (RNA-seq), compare classification performance to conventional histopathology, and test whether RNA-seq-based predictors could add value for patient risk-stratification.Patients and Methods:In total, 3678 breast tumors were studied. For 405 breast tumors in the training cohort, a comprehensive histopathological biomarker evaluation was performed by three pathology readings to estimate inter-pathologist variability on the original diagnostic slides as well as on repeat immunostains for this study, and the consensus biomarker status for all five conventional biomarkers was determined. Whole transcriptome gene expression profiling was performed by RNA-sequencing on the Illumina platform. Using RNA-seq-derived tumor gene expression data as input, single-gene classifiers (SGC) and multi-gene classifiers (MGC) were trained on the consensus pathology biomarker labels. The trained classifiers were tested on an independent prospective population-based series of 3273 primary breast cancer cases from the multicenter SCAN-B study with median 41 months follow-up (ClinicalTrials.gov identifier NCT02306096), and classifications were evaluated by agreement statistics and by Kaplan-Meier and Cox regression survival analyses.Results:For the histopathological evaluation, pathologist evaluation concordance was high for ER, PgR, and HER2 (average kappa values of .920, .891, and .899, respectively), but moderate for Ki67 and NHG (.734 and .581). Classification concordance between RNA-seq classifiers and histopathology for the independent 3273-cohort was similar to that within histopathology assessments, with SGCs slightly outperforming MGCs. Importantly, patients with discordant results, classified as hormone responsive (HoR+) by histopathology but non-hormone responsive by MGC, presented with significantly inferior overall survival compared to patients with concordant results. These results extended to patients with no adjuvant systemic therapy (hazard ratio, HR, 4.54; 95% confidence interval, CI, 1.42-14.5), endocrine therapy alone (HR 3.46; 95% CI, 2.01-5.95), or receiving chemotherapy (HR 2.57; 95% CI 1.13-5.86). For HoR+ cases receiving endocrine therapy alone, the MGC HoR classifier remained significant after multivariable adjustment (HR 3.14; 95% CI, 1.75-5.65).Conclusions:RNA-seq-based classifiers for the five key early breast cancer biomarkers were generally equivalent to conventional histopathology with regards to classification error rate. However, when benchmarked using overall survival, our RNA-seq classifiers provided added clinical value in particular for cases that are determined by histopathology to be hormone-responsive but by RNA-seq appear hormone-insensitive and have a significantly poorer outcome when treated with endocrine therapy alone
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (437)
konferensbidrag (32)
forskningsöversikt (3)
Typ av innehåll
refereegranskat (391)
övrigt vetenskapligt (81)
Borg, Åke (20)
Adami, Hans Olov (13)
Fernö, Mårten (12)
Kaaks, Rudolf (12)
Giles, Graham G (12)
Rydén, Lisa (11)
visa fler...
Saal, Lao (11)
Loman, Niklas (11)
Ehinger, Anna (10)
Wolk, Alicja (10)
Jirström, Karin (10)
Vallon-Christersson, ... (10)
Zeleniuch-Jacquotte, ... (10)
Malmström, Per (9)
Bendahl, Pär Ola (9)
Travis, Ruth C (9)
Höglund, Mattias (9)
Olsson, Håkan (8)
Landberg, Göran (8)
Riboli, Elio (8)
Helleday, Thomas (8)
Larsson, Christer (8)
Chang-Claude, Jenny (7)
Trichopoulou, Antoni ... (7)
Hall, P (7)
Czene, K (7)
Weiderpass, Elisabet ... (7)
Olsson, Anna-Karin (7)
Mitelman, Felix (7)
Lindman, Henrik (7)
Melin, Beatrice S. (7)
Arslan, Alan A (7)
Fall, Katja, 1971- (7)
Kroemer, G (6)
Hartman, Johan (6)
Bergh, Anders (6)
Albanes, Demetrius (6)
Sund, Malin (6)
Easton, DF (6)
Vineis, Paolo (6)
Bueno-de-Mesquita, H ... (6)
Milne, Roger L. (6)
Häkkinen, Jari (6)
Wiklund, F (6)
Micke, Patrick (6)
Peters, Ulrike (6)
Bondy, Melissa L. (6)
Hartge, Patricia (6)
Toniolo, Paolo (6)
Belting, Mattias (6)
visa färre...
Karolinska Institutet (182)
Lunds universitet (126)
Uppsala universitet (125)
Umeå universitet (74)
Linköpings universitet (24)
Kungliga Tekniska Högskolan (21)
visa fler...
Örebro universitet (18)
Göteborgs universitet (11)
Stockholms universitet (10)
Högskolan i Skövde (2)
Högskolan Kristianstad (1)
Mälardalens universitet (1)
Jönköping University (1)
Södertörns högskola (1)
Högskolan i Gävle (1)
Karlstads universitet (1)
Sveriges Lantbruksuniversitet (1)
Röda Korsets Högskola (1)
visa färre...
Engelska (472)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (289)
Naturvetenskap (19)
Lantbruksvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy